Response Durability Analyses from a Rufinamide Pivotal Trial in Lennox-Gastaut Syndrome (LGS) (P2.043)

Conclusions: There was no evidence of tolerance to rufinamide during short-term and long-term treatment. These data support adjunctive rufinamide treatment for multiple seizure types, which may enhance patient adherence. Refs:1Loscher.Epilepsia2006;47:1253-84. Support: Eisai Inc.Disclosure: Dr. Ng has nothing to disclose. Dr. Glauser has received (royalty or license fee or contractual rights) payments from AssureRx Health. Dr. Ferreira has received personal compensation for activities with Eisai Inc. Dr. Olhaye has received personal compensation for activities with Eisai Inc., as an employee. Dr. Williams has received personal compensation for activities with Eisai Inc. as an employee. Mr. Perdomo has received personal compensation for activities with Eisai Inc., as an employee. Dr. Bibbiani has received personal compensation for activities with Eisai Inc. as an employee.

Source: Neurology - April 3, 2016 Category: Neurology Authors: Ng, Y.-t., Glauser, T., Ferreira, J., Olhaye, O., Williams, B., Perdomo, C., Bibbiani, F. Tags: Epilepsy/Clinical Neurophysiology: AEDs Source Type: research